

Fabio M Iwamoto

Professor of Neurology and Neurological Sciences (Adult Neurology) and of Neurosurgery (Adult Neurosurgery)

CLINICAL OFFICE (PRIMARY)

- **Neuro-Oncology**

875 Blake Wilbur Dr

Neuro-Oncology

Stanford, CA 94305

Tel (650) 498-6000 Fax (650) 724-3556

Bio

CLINICAL FOCUS

- Neurology

ACADEMIC APPOINTMENTS

- Professor - Univ Med Line, Adult Neurology
- Professor - Univ Med Line, Neurosurgery

PROFESSIONAL EDUCATION

- Board Certification: Neuro-Oncology, United Council for Neurologic Subspecialties (2013)
- Fellowship: Memorial Sloan-Kettering Cancer Center (2008) NY
- Board Certification: Neurology, American Board of Psychiatry and Neurology (2007)
- Residency: New York Presbyterian Cornell Campus Neurology Residency (2006) NY
- Medical Education: Federal University of Parana (1999) Brazil

Publications

PUBLICATIONS

- **Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Wen, P. Y., Berry, D. A., Buxton, M. B., Colman, H., de Groot, J., Lim, M., Mellinghoff, I., Perry, J. R., Weller, M., Blondin, N. A., Butt, O. H., Damek, D. M., de la Fuente, et al
2026: JCO2501137
- **Multicenter Randomized Phase II Study of R-MPV-A Chemoimmunotherapy With or Without Low-Dose Whole-Brain Radiotherapy for Newly-Diagnosed Primary CNS Lymphoma.** *Neuro-oncology*
Omuro, A., DeAngelis, L. M., Polley, M. C., Correa, D., Wefel, J. S., Bovi, J. A., Rosenblum, M., Corn, B. W., Aneja, S., Grommes, C., Peereboom, D. M., Lallana, E. C., Werner-Wasik, et al
2025
- **TIRABRUTINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE II PROSPECT STUDY**

Nayak, L., Grommes, C., Kallam, A., Peereboom, D., Ambady, P., Mendez, J., Aregawi, D., Sumrall, A., Omuro, A., Iwamoto, F., Dietrich, J., Umemura, Y., Munger, et al
OXFORD UNIV PRESS INC.2025: v135

- **Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study.**
Nayak, L., Grommes, C., Kallam, A., Peereboom, D. M., Ambady, P., Mendez, J. S., Aregawi, D., Sumrall, A., Omuro, A., Iwamoto, F., Dietrich, J., Umemura, Y., Munger, et al
LIPPINCOTT WILLIAMS & WILKINS.2025
- **TUMOR RESPONSES IN A RANDOMIZED PHASE IIB TRIAL OF A CMV VACCINE IMMUNOTHERAPEUTIC CANDIDATE (VBI-1901) IN RECURRENT GLIOBLASTOMAS**
Merrell, R., Wen, P., Forst, D., Schulte, J., Ochia, Y., Bota, D., Nagpal, S., Bonm, A., Diaz-Mitoma, F., Anderson, D., Lassman, A., Iwamoto, F.
OXFORD UNIV PRESS INC.2024
- **Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with <i>BRAF V600</i>-mutated solid tumors**
Piha-Paul, S. A., De La Fuente, M., Iwamoto, F., Nagpal, S., Weise, A. M., Zhu, J., Chandra, S., Chen, C., Fu, Y., Yang, Z., Tsai, K. K.
LIPPINCOTT WILLIAMS & WILKINS.2024
- **GBM AGILE PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GBM: RESULTS OF FIRST EXPERIMENTAL ARM, REGORAFENIB**
Wen, P., Alexander, B., Berry, D., Buxton, M., Cavenee, W., Colman, H., de Groot, J., Ellingson, B., Gordon, G., Hyddmark, E., Khasraw, M., Lim, M., Mellinghoff, et al
OXFORD UNIV PRESS INC.2023
- **MGMT promoter methylation predicts overall survival after chemotherapy for 1p/19q-codeleted gliomas.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Kinslow, C. J., Rae, A. I., Taparra, K., Kumar, P., Siegelin, M. D., Grinband, J., Gill, B. J., McKhann, G. M., Sisti, M. B., Bruce, J. N., Canoll, P. D., Iwamoto, F. M., Horowitz, et al
2023
- **Association of MGMT Promotor Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.** *JAMA oncology*
Kinslow, C. J., Mercurio, A., Kumar, P., Rae, A. I., Siegelin, M. D., Grinband, J., Taparra, K., Upadhyayula, P. S., McKhann, G. M., Sisti, M. B., Bruce, J. N., Canoll, P. D., Iwamoto, et al
2023
- **Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.** *Journal for immunotherapy of cancer*
Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A., Sikic, B. I., Rahma, O., Cho, D. C., Rizvi, N. A., Sznol, M., Lutzky, J., Bauman, J. E., Bitting, R. L., Starodub, et al
2022; 10 (8)
- **TOCA 511 & TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA**
Cloughesy, T., Petrecca, K., Walbert, T., Butowski, N., Salacz, M., Perry, J., Damek, D., Bota, D., Bettegowda, C., Zhu, J., Iwamoto, F., Placantonakis, D., Martinez, et al
OXFORD UNIV PRESS INC.2019: 284
- **Go, no-go decision making for phase 3 clinical trials: ACT IV revisited Reply** *LANCET ONCOLOGY*
Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., Drappatz, J., O'Rourke, D. M., Wong, et al
2017; 18 (12): E709–E710
- **Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.** *The Lancet. Oncology*
Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., Drappatz, J., O'Rourke, D. M., Wong, et al
2017; 18 (12): e709-e710
- **Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial** *LANCET ONCOLOGY*
Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., Drappatz, J., O'Rourke, D. M., Wong, et al

2017; 18 (10): 1373–85

- **ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA**

Weller, M., Butowski, N., Tran, D., Recht, L., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S., Iwamoto, F., Drappatz, J., O'Rourke, D., Wong, et al

OXFORD UNIV PRESS INC.2016: 17